Related Experiment Video
Updated: Jun 15, 2026
09:25
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Osteosarcoma: the European Osteosarcoma Intergroup (EOI) perspective.
1Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK. a.w.craft@ncl.ac.uk
Cancer Treatment and Research
|March 10, 2010
Summary
The European Osteosarcoma Intergroup established chemotherapy regimens for osteosarcoma. Cisplatin/doxorubicin (CDDP/DOX) showed improved survival, but multi-drug regimens had poor adherence, highlighting the need for large international trials.
Area of Science:
- Oncology
- Clinical Trials
- Chemotherapy
Background:
- Osteosarcoma treatment in the late 1970s lacked established chemotherapy protocols.
- Uncertainty existed regarding the efficacy and choice of chemotherapy agents.
Purpose of the Study:
- To establish optimal chemotherapy regimens for osteosarcoma through randomized studies.
- To evaluate different chemotherapy combinations and administration schedules.
Main Methods:
- Conducted three randomized controlled trials (EOI studies 80831, 80861, 80961).
- Compared two-drug (CDDP/DOX) versus three-drug regimens.
- Investigated interval compression of CDDP/DOX with GCSF.
Main Results:
- CDDP/DOX improved survival compared to suboptimal chemotherapy.
- A two-drug CDDP/DOX regimen was superior to a less intense CDDP/DOX/MTX regimen.
- Prolonged multi-drug regimens showed lower treatment adherence than two-drug regimens.
- Interval compression did not improve survival but enhanced histologic response.
Conclusions:
- Established CDDP/DOX as a safe and effective chemotherapy backbone for osteosarcoma.
- Demonstrated challenges with adherence in prolonged, multi-drug regimens.
- Highlighted the need for large, multinational studies to accelerate research in rare diseases like osteosarcoma.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Barrett Esophagus-II: Clinical Manifestations and Management
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...